GALT Chief Medical Officer Khurram Jamil Sells $239K of Stock
Chief Medical Officer Khurram Jamil sold a significant number of shares in Galectin Therapeutics.
Reviewed by automated data checks against the source filing. How we make and check alerts
Khurram Jamil, Chief Medical Officer at Galectin Therapeutics Inc. ($GALT), sold 47,467 shares at an average price of $5.04, worth about $239,233.68, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $GALT is down 6.8% after 1 week, down 29.8% after 1 month and down 27.2% to date (from the $4.97 close on Jun 29, 2026).
GALT
Galectin Therapeutics Inc.
Key Points
- On June 29, 2026, Khurram Jamil, the Chief Medical Officer at Galectin Therapeutics Inc. (GALT), sold 47,467 shares for approximately $239,234 at an average price of $5.04 per share.
- Galectin Therapeutics is currently trading around $4.64, below its recent high of $7.13 and above its 52-week low of $2.03.
- HC Wainwright & Co. maintains a Buy rating on Galectin with a price target of $11.00, highlighting positive sentiment among analysts.
Get $GALT trade alerts by text
We text you when insiders, Congress or big funds trade $GALT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Galectin Therapeutics Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Galectin Therapeutics Inc.
On June 29, 2026, Khurram Jamil, the Chief Medical Officer of Galectin Therapeutics Inc. (GALT), sold 47,467 shares valued at about $239,234. The sale occurred at an average price of $5.04 per share, while the stock was trading at $4.64 on the day the news was published.
Khurram Jamil's Recent Trading Activity
This sale represents a planned transaction for Jamil, who has been active in the stock lately. Earlier, on June 26, 2026, he purchased an additional 4,570 shares at $2.37, bringing his total holdings to 2,533 shares after this recent sale. His prior activity includes several transactions where he bought shares on June 23 and the same day as the sale, totaling 11,160 shares bought in that short span.
Institutional Activity
No other funds reported changes to their positions in Galectin Therapeutics in this filing, as there were no peers listed. This lack of institutional moves might suggest a cautious approach from larger fund managers regarding the stock's volatility.
How Galectin Therapeutics Inc. Stock Has Traded
The stock previously closed at $3.89 before Jamil's sale. It has seen fluctuations, with a 52-week high of $7.13 and a low of $2.03. The current price of $4.64 places it in a middle ground, reflecting investor sentiment and market conditions.
Analysts Set New Price Targets
On June 23, 2026, HC Wainwright & Co. reiterated their Buy rating on Galectin Therapeutics with a price target of $11.00. This rating reflects confidence in the company's potential despite its ongoing challenges in the biotech sector. Analysts have only one opinion currently, indicating a focused view on the stock.
What Galectin Therapeutics Inc. Does
Galectin Therapeutics is a biopharmaceutical company focused on developing new treatments for fibrotic diseases and cancer. Its lead candidate is belapectin, which is currently in clinical trials, suggesting that any insider activity might stem from developments in these studies.
What's Ahead for Galectin Therapeutics Inc.
Investors will be watching for the next earnings report scheduled for August 11, 2025. Note that this insider sale reflects past positions and may not represent ongoing strategies, as the 13F filings are backward-looking.
Related Filing Alerts
Source: Khurram Jamil's Form 4 filing on $GALT (Jun 29, 2026). Find the original filing: GALT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts